Your browser doesn't support javascript.
loading
Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
Pashayan, Nora; Antoniou, Antonis C; Ivanus, Urska; Esserman, Laura J; Easton, Douglas F; French, David; Sroczynski, Gaby; Hall, Per; Cuzick, Jack; Evans, D Gareth; Simard, Jacques; Garcia-Closas, Montserrat; Schmutzler, Rita; Wegwarth, Odette; Pharoah, Paul; Moorthie, Sowmiya; De Montgolfier, Sandrine; Baron, Camille; Herceg, Zdenko; Turnbull, Clare; Balleyguier, Corinne; Rossi, Paolo Giorgi; Wesseling, Jelle; Ritchie, David; Tischkowitz, Marc; Broeders, Mireille; Reisel, Dan; Metspalu, Andres; Callender, Thomas; de Koning, Harry; Devilee, Peter; Delaloge, Suzette; Schmidt, Marjanka K; Widschwendter, Martin.
Afiliação
  • Pashayan N; Department of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London, UK.
  • Antoniou AC; Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Ivanus U; Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
  • Esserman LJ; Carol Franc Buck Breast Care Center, University of California, San Francisco, CA, USA.
  • Easton DF; Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • French D; Division of Psychology & Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.
  • Sroczynski G; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT-University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria.
  • Hall P; Division of Health Technology Assessment, Oncotyrol - Center for Personalized Cancer Medicine, Innsbruck, Austria.
  • Cuzick J; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Evans DG; Department of Oncology, Södersjukhuset, Stockholm, Sweden.
  • Simard J; Wolfson Institute of Preventive Medicine, Barts and The London, Centre for Cancer Prevention, Queen Mary University of London, London, UK.
  • Garcia-Closas M; Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK.
  • Schmutzler R; Genomics Center, CHU de Québec - Université Laval Research Center, Québec, Canada.
  • Wegwarth O; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Pharoah P; Center of Family Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany.
  • Moorthie S; Max Planck Institute for Human Development, Center for Adaptive Rationality, Harding Center for Risk Literacy, Berlin, Germany.
  • De Montgolfier S; Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Baron C; Department of Oncology, University of Cambridge, Cambridge, UK.
  • Herceg Z; PHG Foundation, Cambridge, UK.
  • Turnbull C; IRIS Institute for Interdisciplinary Research on Social Issues, Paris, France.
  • Balleyguier C; Unicancer, Paris, France.
  • Rossi PG; Epigenetic Group, International Agency for Research on Cancer (IARC), WHO, Lyon, France.
  • Wesseling J; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
  • Ritchie D; Department Medical Imaging, Institut Gustave Roussy, Villejuif, France.
  • Tischkowitz M; Epidemiology Unit, Azienda USL di Reggio Emilia - IRCCS, Reggio Emilia, Italy.
  • Broeders M; Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
  • Reisel D; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
  • Metspalu A; Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
  • Callender T; Department for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands.
  • de Koning H; Department of Women's Cancer, Institute for Women's Health, University College London, London, UK.
  • Devilee P; The Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.
  • Delaloge S; Department of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London, UK.
  • Schmidt MK; Department of Public Health, Erasmus MC, Rotterdam, Netherlands.
  • Widschwendter M; Department of Human Genetics, Department of Pathology, Leiden University Medical Centre, Leiden, Netherlands.
Nat Rev Clin Oncol ; 17(11): 687-705, 2020 11.
Article em En | MEDLINE | ID: mdl-32555420
ABSTRACT
The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast cancer. In a consensus conference held in 2019, the members of this network identified research areas requiring development to enable evidence-based personalized interventions that might improve the benefits and reduce the harms of existing breast cancer screening and prevention programmes. The priority areas identified were 1) breast cancer subtype-specific risk assessment tools applicable to women of all ancestries; 2) intermediate surrogate markers of response to preventive measures; 3) novel non-surgical preventive measures to reduce the incidence of breast cancer of poor prognosis; and 4) hybrid effectiveness-implementation research combined with modelling studies to evaluate the long-term population outcomes of risk-based early detection strategies. The implementation of such programmes would require health-care systems to be open to learning and adapting, the engagement of a diverse range of stakeholders and tailoring to societal norms and values, while also addressing the ethical and legal issues. In this Consensus Statement, we discuss the current state of breast cancer risk prediction, risk-stratified prevention and early detection strategies, and their implementation. Throughout, we highlight priorities for advancing each of these areas.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Idioma: En Ano de publicação: 2020 Tipo de documento: Article